Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis

PloS One
Wenlan ChenQiubai Li

Abstract

The prognostic significance of KIT mutations in core-binding factor acute myeloid leukemia (CBF-AML), including inv(16) and t(8;21) AML, is uncertain. We performed a systematic review and meta-analysis of the effect of KIT mutations on the complete remission (CR) and relapse rates and overall survival (OS) of CBF-AML. PubMed, Embase, Web of Science, and the Cochrane Library were searched and relevant studies were included. Negative effect was indicated on relapse risk of CBF-AML (RR [relative risk], 1.43; 95%CI [confidence interval], 1.20-1.70) and t(8;21) AML (RR, 1.70; 95% CI, 1.31-2.21), not on OS of CBF-AML (RR, 1.09; 95% CI, 0.97-1.23), CR (OR [odds ratio], 0.95; 95% CI, 0.52-1.74), relapse risk (RR, 1.12; 95% CI, 0.90-1.41) or OS (RR, 1.03; 95% CI, 0.90-1.18) of inv(16) AML. Subgroup analysis of t(8,21) AML showed negative effect of KIT mutations on CR (OR, 2.03; 95%CI: 1.02-4.05), relapse risk (RR, 1.89; 95%CI: 1.51-2.37) and OS (RR, 2.26; 95%CI: 1.35-3,78) of non-Caucasians, not on CR (OR, 0.61; 95%CI: 0.19-1.95) or OS (RR, 1.12; 95%CI: 0.90-1.40) of Caucasians. This study indicates KIT mutations in CBF-AML to be included in the initial routine diagnostic workup and stratification system of t(8,21) AML. Prospective larg...Continue Reading

References

May 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonM J Keating
Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Jul 12, 2002·Statistics in Medicine·Julian P T Higgins, Simon G Thompson
Sep 6, 2003·BMJ : British Medical Journal·Julian P T HigginsDouglas G Altman
Mar 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John C ByrdClara D Bloomfield
Aug 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciClara D Bloomfield
Apr 7, 2006·Leukemia·N BoisselUNKNOWN Leucémies Aiguës Myéloblastiques de l'Enfant (LAME) Cooperative Groups
Aug 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter PaschkaUNKNOWN Cancer and Leukemia Group B
Aug 12, 2008·Seminars in Oncology·Peter Paschka
Mar 6, 2009·PLoS Medicine·Gurdeep S SagooJulian P T Higgins
Jan 13, 2010·British Journal of Haematology·Sonja C LückLars Bullinger
Jul 1, 2011·Leukemia Research·Sang Hyuk ParkChan-Jeoung Park
Oct 31, 2012·Biochemical and Biophysical Research Communications·Di WangJianfeng Zhou
Mar 8, 2013·Oncology Reports·Ludovica RieraAchille Pich
Apr 27, 2013·American Journal of Hematology·Roberto CairoliEnrica Morra
Dec 10, 2013·Hematology·Peter Paschka, Konstanze Döhner

❮ Previous
Next ❯

Citations

Apr 12, 2017·Current Hematologic Malignancy Reports·Cecilia C S Yeung, Jerald Radich
Jun 15, 2019·Journal of the National Comprehensive Cancer Network : JNCCN·Martin S TallmanNdiya Ogba
Jul 25, 2019·International Journal of Molecular Sciences·Solène FernandezPierre-Yves Dumas
Aug 23, 2020·Current Opinion in Oncology·Shristi Upadhyay BanskotaVijaya Raj Bhatt
Jun 12, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Katherine TarlockJessica A Pollard
Jan 7, 2021·Journal of the National Comprehensive Cancer Network : JNCCN·Daniel A PollyeaMartin S Tallman
Jan 12, 2021·Frontiers in Oncology·Vanessa E Kennedy, Catherine C Smith
Jan 9, 2018·Leukemia Research·Stephen A StricklandAdam C Seegmiller

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Software Mentioned

STATA
RevMan

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.